Figure 1.

Dihydromyricetin (DHM) inhibits activation of microglia in APP/PS1 mice. A‐C, DHM reduces the number of activated microglia in the hippocampus and cortex of DHM treatment groups. Compared with the 2‐week group, the 4‐week group showed a more pronounced decrease. Data are presented as mean ± SEM, *P < .05, ***P < .001, Scale bars: 40 μm. D, E, Western blot analysis showing a decrease in ED1 protein levels in DHM‐treated groups compared with control groups (*P < .05, ***P < .001 vs control group)